Shanton Pharma PTE. LTD.

Single-Patient EA Policies/Criteria Shanton Pharma PTE. LTD. (‘Shanton’) is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare and seriously debilitating diseases. We currently have a late-stage investigational medicine in our product pipeline for the treatment of refractory/tophaceous gout. Our goal is to provide access to our product at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe that enrollment of the relevant patient population in our ongoing clinical trials is the safest and most effective way to achieve this goal, and we encourage all patients and physicians to find out about enrollment details of our clinical trials by visiting the clinicaltrials.gov website. [ https://clinicaltrials.gov/search?term=Shanton ] However, we recognize that some patients will not be eligible for our clinical trials and may wish to access our product through expanded access. At this time, the Shanton Expanded Access Program is under development. We will update this page with additional information on this program once it is available. If you have any questions, please reach out to us via email at contactus_us@shantonpharma.com . You can find further contact details on the Contact Us page of our website [ https://www.shantonpharma.com/ ].